• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

充分利用复杂性创造机遇：非小细胞肺癌（NSCLC）患者的综合基因组分析与分子肿瘤学委员会

Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC).

作者信息

Fumagalli Caterina, Guerini-Rocco Elena, Barberis Massimo

机构信息

Division of Pathology, IEO, European Institute of Oncology, IRCCS, 20141 Milano, Italy.

Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.

出版信息

Cancers (Basel). 2021 Feb 4;13(4):609. doi: 10.3390/cancers13040609.

DOI:10.3390/cancers13040609
PMID:33557047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7913872/
Abstract

Personalized cancer therapy matches the plan of treatment with specific molecular alterations [...].

摘要

个性化癌症治疗将治疗方案与特定的分子改变相匹配[……]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4280/7913872/be1b250c0234/cancers-13-00609-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4280/7913872/be1b250c0234/cancers-13-00609-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4280/7913872/be1b250c0234/cancers-13-00609-g001.jpg

相似文献

1
Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC).充分利用复杂性创造机遇：非小细胞肺癌（NSCLC）患者的综合基因组分析与分子肿瘤学委员会
Cancers (Basel). 2021 Feb 4;13(4):609. doi: 10.3390/cancers13040609.
2
Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.综合基因组分析有助于实施美国国立综合癌症网络肺癌生物标志物检测指南，并识别可能从参与机制驱动的临床试验中获益的患者。
Oncologist. 2016 Jun;21(6):684-91. doi: 10.1634/theoncologist.2016-0030. Epub 2016 May 5.
3
Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).与非小细胞肺癌脑转移风险增加相关的基因：61 例脑转移瘤与原发性非小细胞肺癌（广东胸部肿瘤研究学会 1036 项研究）的综合基因组分析
Cancer. 2019 Oct 15;125(20):3535-3544. doi: 10.1002/cncr.32372. Epub 2019 Jul 9.
4
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.中国非小细胞肺癌中靶向下一代测序鉴定的驱动基因的基因组特征。
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.
5
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
6
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.综合基因组分析鉴定出一组荧光原位杂交未检测到的对克唑替尼敏感的ALK重排非小细胞肺癌。
Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.
7
Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.日本分子肿瘤委员会对综合基因组分析检测的临床决策：一项回顾性观察研究。
Cancer Med. 2023 Mar;12(5):6170-6181. doi: 10.1002/cam4.5349. Epub 2022 Oct 17.
8
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue. aspiration：澳大利亚观察性队列研究，对转移性肺癌组织进行全面基因组分析 profiling
Future Oncol. 2024 Mar;20(7):361-371. doi: 10.2217/fon-2023-0366. Epub 2023 Sep 28.
9
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.非小细胞肺癌中新靶向改变的检测优化的共识推荐建议。
Curr Oncol. 2022 Jul 15;29(7):4981-4997. doi: 10.3390/curroncol29070396.
10
Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.亚洲晚期非小细胞肺癌应用循环肿瘤 DNA 进行基因组分析的临床应用
Clin Lung Cancer. 2018 Sep;19(5):e601-e608. doi: 10.1016/j.cllc.2018.04.022. Epub 2018 May 7.

引用本文的文献

1
Diagnostic and Predictive Biomarkers in Lung Cancer.肺癌的诊断和预测生物标志物
Cancers (Basel). 2021 May 25;13(11):2577. doi: 10.3390/cancers13112577.

本文引用的文献

1
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.分子肿瘤专家委员会对具有罕见或复杂突变特征的非小细胞肺癌患者的建议的相关性和有效性
JCO Precis Oncol. 2020 Nov;4:393-410. doi: 10.1200/PO.20.00008.
2
Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.在社区环境中建立分子肿瘤委员会（MTB）及建议的采纳情况。
J Pers Med. 2020 Nov 27;10(4):252. doi: 10.3390/jpm10040252.
3
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
荷兰分子肿瘤委员会的多中心比较：定义、组成、方法及靶向治疗建议
Oncologist. 2021 Aug;26(8):e1347-e1358. doi: 10.1002/onco.13580. Epub 2020 Nov 10.
4
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.分子肿瘤委员会的真实世界数据表明，采用精准 N-of-One 策略可改善预后。
Nat Commun. 2020 Oct 2;11(1):4965. doi: 10.1038/s41467-020-18613-3.
5
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer.比较三种商业决策支持平台，以匹配癌症患者的下一代测序结果与治疗方法。
ESMO Open. 2020 Sep;5(5):e000872. doi: 10.1136/esmoopen-2020-000872.
6
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.精准肿瘤学中指导临床决策的支持系统：欧洲癌症核心分子肿瘤学委员会门户网站。
Nat Med. 2020 Jul;26(7):992-994. doi: 10.1038/s41591-020-0969-2.
7
Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT).精准医学时代肺癌的分子与基因组分析：来自意大利胸科肿瘤学会（AIOT）的立场文件
Cancers (Basel). 2020 Jun 19;12(6):1627. doi: 10.3390/cancers12061627.
8
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice.真实世界临床实践中综合基因组分析的影响与诊断差距
Cancers (Basel). 2020 May 4;12(5):1156. doi: 10.3390/cancers12051156.
9
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock.晚期非小细胞肺癌的广泛基因组测序正在进行中。
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S360-S363. doi: 10.21037/tlcr.2019.04.16.
10
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients.一个虚拟分子肿瘤委员会，旨在提高为医生及其患者提供精准肿瘤学服务的效率和可扩展性。
JAMIA Open. 2019 Oct 7;2(4):505-515. doi: 10.1093/jamiaopen/ooz045. eCollection 2019 Dec.